Amgen Inc. (LON:0R0T)

Market Cap	131.81B
Revenue (ttm)	26.76B
Net Income (ttm)	5.21B
Shares Out	n/a
EPS (ttm)	9.62
PE Ratio	25.29
Forward PE	15.68
Dividend	7.26 (2.21%)
Ex-Dividend Date	Nov 21, 2025

Volume	941
Average Volume	1,136
Open	324.95
Previous Close	324.02
Day's Range	321.01 - 330.48
52-Week Range	253.20 - 348.94
Beta	n/a
RSI	53.51
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R0T

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD